Pipeline

2013+

• June 2013 - Spun-off from Cedars-Sinai Medical Center
• June 2014 - Raised $525k from Founders / Pennsylvania Biotechnology Grant
• July 2016 - Name changed to Kairos Pharma and licensed immunotherapy technology from Cedars-Sinai Medical Center
• November 2019 - Merged with AcTcell Biopharma
• July 2021 - Merged with Enviro Therapeutics

2022

• Preclinical work for ENV105 Prostate Cancer Phase II, ENV105 Non-Small Cell Lung Cancer Phase I, KROS-201 Glioblastoma Phase I
• IND for KROS 201 cleared for recurrent glioblastoma

2023

• KROS-101 GITR agonist molecule and KROS-102 antagonist GITR molecule Preclinical studies
• IND approved for Phase II Prostate Cancer Trial and for Phase I Non-Small Cell Lung Cancer for ENV 105

2024

• Phase I and II multi-center trials with ENV 105 enrolling
• Preclinical development of KROS 101, 102, 301, 401
• Safety data from Phase II trial and Phase I trial

2025

• Efficacy data from Phase II trial and Phase I trial
• 5-year Horizon for ENV105 FDA Approval with a Maturing Pipeline of Broader Prospective Applications
• Phase I trials for KROS 101